MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Novartis AG

Abrir

132.92 1.62

Visão Geral

Variação de preço das ações

24h

Atual

Mín

129.91

Máximo

132.45

Indicadores-chave

By Trading Economics

Rendimento

418M

4B

Vendas

660M

14B

P/E

Médio do Setor

18.012

35.739

EPS

2.42

Rendimento de Dividendos

3.23

Margem de lucro

28.18

Funcionários

75,883

EBITDA

-5.8B

4.9M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-13.64% downside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.23%

3.08%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.2B

240B

Abertura anterior

131.3

Fecho anterior

132.92

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Novartis AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de out. de 2025, 08:54 UTC

Grandes Movimentos do Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

15 de set. de 2025, 12:07 UTC

Grandes Movimentos do Mercado

Monte Rosa Therapeutics Shares Soar on Drug Partnership with Novartis

9 de set. de 2025, 10:11 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

Tourmaline Bio Shares Surge Premarket on Takeover by Novartis

9 de set. de 2025, 05:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

7 de ago. de 2025, 05:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17 de jul. de 2025, 14:26 UTC

Ganhos

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 de jul. de 2025, 06:49 UTC

Ganhos

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 de jul. de 2025, 05:41 UTC

Ganhos

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

1 de out. de 2025, 06:47 UTC

Conversa de Mercado

Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk

29 de set. de 2025, 11:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Offer to Expire Oct. 27

29 de set. de 2025, 11:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis Has Started Tender Offer to Buy Tourmaline Bio

12 de set. de 2025, 16:11 UTC

Ganhos

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

9 de set. de 2025, 08:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Novartis Makes Strategically Meaningful Move With Tourmaline Deal -- Market Talk

9 de set. de 2025, 05:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis Offering $48 a Share for Tourmaline

9 de set. de 2025, 05:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Offer Price Values Tourmaline at $1.4B on Fully Diluted Basis

9 de set. de 2025, 05:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Tourmaline Bio in Bid to Complement Cardiovascular Pipeline

9 de set. de 2025, 05:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Tourmaline Bio

11 de ago. de 2025, 11:16 UTC

Ganhos

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus -- WSJ

8 de ago. de 2025, 11:26 UTC

Conversa de Mercado

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8 de ago. de 2025, 11:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8 de ago. de 2025, 10:51 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5 de ago. de 2025, 10:40 UTC

Conversa de Mercado

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17 de jul. de 2025, 11:36 UTC

Conversa de Mercado

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 de jul. de 2025, 11:26 UTC

Conversa de Mercado

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 de jul. de 2025, 07:14 UTC

Conversa de Mercado

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 de jul. de 2025, 07:02 UTC

Conversa de Mercado
Ganhos

Novartis's Results Look Impressive -- Market Talk

17 de jul. de 2025, 05:09 UTC

Ganhos

Novartis 2Q Sales Grew 11% at Constant Currency

17 de jul. de 2025, 05:08 UTC

Ganhos

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 de jul. de 2025, 05:06 UTC

Ganhos

Novartis: Mehta's Appointment Is Effective March 2026

17 de jul. de 2025, 05:05 UTC

Ganhos

Novartis: Harry Kirsch Retires After 22 Years With Company

Comparação entre Pares

Variação de preço

Novartis AG Previsão

Preço-alvo

By TipRanks

-13.64% parte inferior

Previsão para 12 meses

Média 113.75 USD  -13.64%

Máximo 129 USD

Mínimo 100 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Novartis AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 112.63Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
help-icon Live chat